Ariad Pharmaceuticals Inc fka ARIA

[adreamer]

Rodman & Renshaw maintained its ARIAD Pharmaceuticals (NASDAQ: ARIA [2]) Market Outperform rating and $18 price target in a research report published today.

In the report, Rodman & Renshaw stated, "We continue to believe investors have not realized the full economic potential of ponatinib, or that ARIA likely will have two approved products on the market in the US and EU by 2013 with another drug in a pivotal trial."

Shares of ARIAD Pharmaceuticals were trading at $14.42 at the time of posting, down 4.88% from Monday's market close.